サンプル依頼リスト カート
  • English
  • Korean
表紙：ニボルマブの世界市場レポート 2024年
市場調査レポート
商品コード
1415759

ニボルマブの世界市場レポート 2024年

Nivolumab Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
ニボルマブの世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

ニボルマブの市場規模は近年急速に拡大しています。2023年の14億7,000万米ドルから2024年には16億9,000万米ドルへ、CAGR15.1％で拡大します。実績期間の成長は、免疫療法の進歩、がんの罹患率の増加、臨床試験の成功、規制当局の承認に起因しています。

ニボルマブ市場規模は、今後数年で急成長が見込まれます。2028年にはCAGR13.6％で28億1,000万米ドルに成長します。予測期間の成長は、個別化医療、新たな適応症、世界のがん治療へのアクセス、併用療法の進歩に起因しています。予測期間における主な動向としては、バイオマーカー主導型治療、新抗原ワクチン、免疫療法レジメンの強化、長期追跡調査などが挙げられます。

ニボルマブ市場の成長は、がん罹患率の増加によって大きく促進されます。がんは、体内のほぼすべての臓器や組織に発現する可能性のある広範な疾患を包含します。がんは異常細胞の無秩序な増殖を特徴とし、その異常細胞は通常の境界を突破し、他の臓器への転移や近隣組織への浸潤の可能性があります。ニボルマブは、がん治療のキープレイヤーであり、がん細胞が免疫系を抑制するのを防ぐことによって機能し、それによって免疫系がこれらの悪性細胞を識別し、標的とし、排除することを可能にします。その一例として、米国に本部を置く非営利の健康団体である米国がん協会（American Cancer Society Inc.）は、2023年には米国で新たに診断されるがん患者は190万人に達し、2020年の180万人よりも増加すると予測しています。その結果、がんの急増はニボルマブ市場拡大の強力な原動力となっています。

非小細胞肺がん（NSCLC）の罹患率の増加は、当面のニボルマブ市場成長の顕著な促進要因になると予測されています。NSCLCは、肺の上皮細胞から発生する肺がんの一種で、ニボルマブが注力している領域です。ニボルマブは、進行した非小細胞肺がん（NSCLC）の治療薬として承認されており、その有効性が証明されています。米国臨床腫瘍学会のデータによると、2023年3月に米国で肺がんと診断される患者は238,340人（男性117,550人、女性120,790人）と推定されています。これらの症例のうち、NSCLCが優勢なサブタイプであり、肺がん診断全体の約81％を占める。その結果、非小細胞肺がん（NSCLC）の罹患率の増加は、ニボルマブ市場の手ごわい成長促進要因となっています。

2023年のニボルマブ市場で最大の地域は北米でした。ニボルマブレポートの対象地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界のニボルマブ市場、タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • 注射用4mL
  • 注射用10mL
  • 世界のニボルマブ市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 静脈内
  • その他
  • 世界のニボルマブ市場、アプリケーション別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • 黒色腫
  • 非小細胞肺がん（NSCLC）
  • 悪性胸膜中皮腫
  • 古典的ホジキンリンパ腫（CHL）
  • 頭頸部扁平上皮がん（SCCHN）
  • 腎細胞がん（RCC）
  • その他の用途
  • 世界のニボルマブ市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • 診療所
  • 病院
  • その他のエンドユーザー

第7章 地域および国の分析

  • 世界のニボルマブ市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
  • 世界のニボルマブ市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • ニボルマブ市場の競合情勢
  • ニボルマブ市場の企業プロファイル
    • Pfizer Inc.
    • Johnson &Johnson Services Inc.
    • F. Hoffmann-La Roche Ltd.
    • Merck &Co. Inc.
    • AbbVie Inc.

第31章 その他の主要および革新的な企業

  • Novartis AG
  • Sanofi S.A.
  • Bristol-Myers Squibb Company
  • AstraZeneca plc
  • GlaxoSmithKline plc
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Amgen Inc.
  • Regeneron Pharmaceuticals Inc.
  • Astellas Pharma Inc.
  • Chugai Pharmaceutical Co. Ltd.
  • Daiichi Sankyo Company Limited
  • Eisai Co. Ltd.
  • Ono Pharmaceutical Co. Ltd.
  • Kyowa Kirin Co. Ltd.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r12358

“Nivolumab Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on nivolumab market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for nivolumab? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The nivolumab market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Type: Injection 4mL; Injection 10mL
  • 2) By Route Of Administration: Intravenous; Other Routes Of Administration
  • 3) By Application: Melanoma; Non-small Cell Lung Cancer (NSCLC); Malignant Pleural Mesothelioma; Classical Hodgkin Lymphoma (CHL); Squamous Cell Carcinoma Of The Head And Neck (SCCHN); Renal Cell Carcinoma (RCC); Other Applications
  • 4) By End-User: Clinic; Hospital; Other End-Users
  • Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Nivolumab is an immunoglobulin G4 (IgG4) fully human antibody that targets programmed cell death protein 1 (PD1). It is approved at a dosage of 3 mg/kg for the treatment of metastatic or unresectable melanoma, metastatic non-small cell lung cancer following platinum-based chemotherapy, and metastatic renal cell carcinoma in the second-line setting. Nivolumab is a targeted therapy medication employed in the management and treatment of various types of cancer, and it operates by enhancing the immune system's response to cancer cells.

Nivolumab is available in two main formulations such as an injection of 4 mL and an injection of 10 mL. The 40 mg/4 mL (10 mg/mL) solution of nivolumab is provided in single-use vials. This formulation is utilized in the treatment of melanoma, non-small cell lung cancer (NSCLC), and Hodgkin lymphoma. It is administered via intravenous and other routes for the treatment of conditions such as melanoma, NSCLC, malignant pleural mesothelioma, classical Hodgkin lymphoma (CHL), squamous cell carcinoma of the head and neck (SCCHN), renal cell carcinoma (RCC), and other cancer types. Nivolumab is used in clinical settings, hospitals, and other healthcare facilities for cancer treatment.

The nivolumab market research report is one of a series of new reports from The Business Research Company that provides nivolumab market statistics, including nivolumab industry global market size, regional shares, competitors with a nivolumab market share, detailed nivolumab market segments, market trends and opportunities and any further data you may need to thrive in the nivolumab industry. This nivolumab market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The nivolumab market size has grown rapidly in recent years. It will grow from $1.47 billion in 2023 to $1.69 billion in 2024 at a compound annual growth rate (CAGR) of 15.1%. The growth in the historic period can be attributed to immunotherapy advancements, increased incidence of cancer, clinical trial success, regulatory approvals.

The nivolumab market size is expected to see rapid growth in the next few years. It will grow to $2.81 billion in 2028 at a compound annual growth rate (CAGR) of 13.6%. The growth in the forecast period can be attributed to personalized medicine, emerging indications, global access to cancer care, advancements in combination therapies. Major trends in the forecast period include biomarker-driven treatment, neoantigen vaccines, enhanced immunotherapy regimens, long-term follow-up studies.

The growth of the nivolumab market is set to be significantly propelled by the increasing prevalence of cancer. Cancer encompasses a broad spectrum of diseases that can manifest in nearly any organ or tissue within the body. It is characterized by the uncontrolled proliferation of abnormal cells, which can breach their usual boundaries and have the potential to metastasize to other organs or infiltrate neighboring tissues. Nivolumab, a key player in cancer treatment, functions by preventing cancer cells from suppressing the immune system, thereby enabling the immune system to identify, target, and eliminate these malignant cells. As an illustrative instance, the American Cancer Society Inc., a non-profit health organization based in the United States, predicts that in 2023, there will be a staggering 1.9 million new cancer cases diagnosed in the U.S., marking an increase compared to the over 1.8 million cases identified in 2020. Consequently, the burgeoning prevalence of cancer serves as a robust driving force behind the expansion of the nivolumab market.

The increasing incidence of non-small cell lung cancer (NSCLC) is poised to be a prominent driver for the Nivolumab market's growth in the foreseeable future. NSCLC, a prevalent form of lung cancer originating in the epithelial cells of the lungs, is a major area of focus for Nivolumab. The drug has garnered approval for the treatment of advanced non-small cell lung cancer (NSCLC) owing to its proven efficacy in addressing this specific condition. Notably, data from the American Society of Clinical Oncology reveals that an estimated 238,340 individuals (comprising 117,550 men and 120,790 women) are anticipated to receive a lung cancer diagnosis in the United States in March 2023. Among these cases, NSCLC is the predominant subtype, representing approximately 81% of all lung cancer diagnoses. Consequently, the increased incidence of non-small cell lung cancer (NSCLC) stands as a formidable growth driver for the Nivolumab market.

The primary hurdle constraining market growth during the forecast period is the potential immune-related adverse events (IR-AEs) associated with Nivolumab usage. Nivolumab, known as an immune checkpoint inhibitor, has emerged as an innovative therapeutic option for cancer treatment. However, it is accompanied by several IR-AEs, including thyroid complications, colitis, pneumonitis, and, though rare, conditions such as type 1 diabetes, Guillain-Barre syndrome, and myasthenia gravis. The elevated incidence of IR-AEs linked to Nivolumab administration raises concerns regarding their potential increase as Nivolumab usage expands. For instance, in July 2021, the US-based pharmaceutical company Bristol-Myers Squibb made the challenging decision to voluntarily withdraw Opdivo (nivolumab) from the U.S. market as a monotherapy for individuals with hepatocellular carcinoma (HCC) who had previously received sorafenib treatment. Thus, the limiting factor influencing the Nivolumab market's growth is the possible immune-related adverse events associated with its utilization.

Prominent companies operating within the Nivolumab market are placing a significant emphasis on the development of innovative drugs aimed at enhancing patient care and sustaining their market positions. The creation of novel drugs holds the potential to improve treatment outcomes for patients grappling with various medical conditions. As an illustration, in May 2022, Bristol-Myers Squibb Co., a US-based pharmaceutical company primarily dedicated to therapeutic endeavors encompassing cancer, cardiovascular health, immunology, and fibrotic conditions, disclosed the FDA's approval of two Nivolumab-based regimens. These regimens included Nivolumab in combination with fluoropyrimidine and platinum-containing chemotherapy and Nivolumab paired with Yervoy (ipilimumab), for the first-line treatment of adult patients dealing with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC), regardless of PD-L1 status.

In November 2022, Lyvgen Biopharma Co. Ltd., a China-based biotechnology firm specializing in cancer treatment, entered into a collaborative partnership with Bristol-Myers Squibb Co. The collaboration's focal point is the assessment of LVGN7409 in conjunction with Nivolumab, targeting patients with non-small cell lung cancer. This combination therapy concurrently addresses the co-stimulatory checkpoint CD40 and the co-inhibitory checkpoint PD-1. This multifaceted approach is envisioned to enhance the effectiveness of immunotherapy for patients confronting diseases that exhibit resistance or refractoriness. Bristol-Myers Squibb Co. is a US-based pharmaceutical company with a primary focus on therapeutic domains spanning cancer, cardiovascular health, immunology, and fibrotic disorders, inclusive of pioneering developments in Nivolumab.

Major players in the nivolumab market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ono Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Nippon Kayaku Co. Ltd., Luye Pharma AG, Genentech Inc., Taiho Pharmaceutical Co. Ltd., SymBio Pharmaceuticals Ltd., Xbrane Biopharma AB, NeuClone Therapeutics Inc.

North America was the largest region in the nivolumab market in 2023. The regions covered in nivolumab report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the nivolumab market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The nivolumab market consists of sales of opdivo, nivolumab injection, generic Nivolumab. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Nivolumab Market Characteristics

3. Nivolumab Market Trends And Strategies

4. Nivolumab Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Nivolumab Market Size and Growth

  • 5.1. Global Nivolumab Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Nivolumab Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Nivolumab Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Nivolumab Market Segmentation

  • 6.1. Global Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Injection 4mL
  • Injection 10mL
  • 6.2. Global Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Intravenous
  • Other Routes Of Administration
  • 6.3. Global Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Melanoma
  • Non-small Cell Lung Cancer (NSCLC)
  • Malignant Pleural Mesothelioma
  • Classical Hodgkin Lymphoma (CHL)
  • Squamous Cell Carcinoma Of The Head And Neck (SCCHN)
  • Renal Cell Carcinoma (RCC)
  • Other Applications
  • 6.4. Global Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Clinic
  • Hospital
  • Other End-Users

7. Nivolumab Market Regional And Country Analysis

  • 7.1. Global Nivolumab Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Nivolumab Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Nivolumab Market

  • 8.1. Asia-Pacific Nivolumab Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Nivolumab Market

  • 9.1. China Nivolumab Market Overview
  • 9.2. China Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Nivolumab Market

  • 10.1. India Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Nivolumab Market

  • 11.1. Japan Nivolumab Market Overview
  • 11.2. Japan Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Nivolumab Market

  • 12.1. Australia Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Nivolumab Market

  • 13.1. Indonesia Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Nivolumab Market

  • 14.1. South Korea Nivolumab Market Overview
  • 14.2. South Korea Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Nivolumab Market

  • 15.1. Western Europe Nivolumab Market Overview
  • 15.2. Western Europe Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Nivolumab Market

  • 16.1. UK Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Nivolumab Market

  • 17.1. Germany Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Nivolumab Market

  • 18.1. France Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Nivolumab Market

  • 19.1. Italy Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Nivolumab Market

  • 20.1. Spain Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Nivolumab Market

  • 21.1. Eastern Europe Nivolumab Market Overview
  • 21.2. Eastern Europe Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Nivolumab Market

  • 22.1. Russia Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Nivolumab Market

  • 23.1. North America Nivolumab Market Overview
  • 23.2. North America Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Nivolumab Market

  • 24.1. USA Nivolumab Market Overview
  • 24.2. USA Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Nivolumab Market

  • 25.1. Canada Nivolumab Market Overview
  • 25.2. Canada Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Nivolumab Market

  • 26.1. South America Nivolumab Market Overview
  • 26.2. South America Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Nivolumab Market

  • 27.1. Brazil Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Nivolumab Market

  • 28.1. Middle East Nivolumab Market Overview
  • 28.2. Middle East Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Nivolumab Market

  • 29.1. Africa Nivolumab Market Overview
  • 29.2. Africa Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Nivolumab Market Competitive Landscape And Company Profiles

  • 30.1. Nivolumab Market Competitive Landscape
  • 30.2. Nivolumab Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson & Johnson Services Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. F. Hoffmann-La Roche Ltd.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Merck & Co. Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. AbbVie Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Nivolumab Market Other Major And Innovative Companies

  • 31.1. Novartis AG
  • 31.2. Sanofi S.A.
  • 31.3. Bristol-Myers Squibb Company
  • 31.4. AstraZeneca plc
  • 31.5. GlaxoSmithKline plc
  • 31.6. Takeda Pharmaceutical Company Limited
  • 31.7. Eli Lilly and Company
  • 31.8. Amgen Inc.
  • 31.9. Regeneron Pharmaceuticals Inc.
  • 31.10. Astellas Pharma Inc.
  • 31.11. Chugai Pharmaceutical Co. Ltd.
  • 31.12. Daiichi Sankyo Company Limited
  • 31.13. Eisai Co. Ltd.
  • 31.14. Ono Pharmaceutical Co. Ltd.
  • 31.15. Kyowa Kirin Co. Ltd.

32. Global Nivolumab Market Competitive Benchmarking

33. Global Nivolumab Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Nivolumab Market

35. Nivolumab Market Future Outlook and Potential Analysis

  • 35.1 Nivolumab Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Nivolumab Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Nivolumab Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer